Finally, we validated these NOG signatures using the independent TCGA-CPTAC set (the validation set 2) which contains 295 additional ER+ breast cancer samples (Figure 7C, P = 1.2 × 10−3; Table 1, Table S12). This evidence concerns the gene ESR1 and breast carcinoma.